Detalhe da pesquisa
1.
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Blood
; 132(11): 1125-1133, 2018 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30045838
2.
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Blood
; 123(21): 3239-46, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24687088
3.
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Biol Blood Marrow Transplant
; 17(3): 341-50, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20685259
4.
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.
Leukemia
; 34(11): 2981-2991, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32409689
5.
Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.
Blood Adv
; 2(4): 381-389, 2018 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29467192
6.
Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.
Leukemia
; 32(9): 2049-2054, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29588547